Abstract: Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition.

Abstract: Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologs and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition.

Abstract: Pharmaceutical compositions and single unit dosage forms of apremilast, i.e., (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders ameliorated by the inhibition of TNF-? production in mammals.

Abstract: The present invention relates to agricultural methods and the use of an insecticidal active carboxamide derivative in seed treatment and soil application methods. The insecticidal carboxamide derivative is highly suitable alone or in combination with other active agricultural ingredients for controlling animal pests such as insects and/or spider mites and/or nematodes by treating the soil/growth substrate by drenching or drip application or dipping or soil injection.

Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

Abstract: Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition.

Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

Abstract: Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.

Abstract: Pharmaceutical compositions and single unit dosage forms of apremilast, i.e., (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders ameliorated by the inhibition of TNF-? production in mammals.

Abstract: Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition.

Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

Abstract: Methos and systems for configuring a plurality of colors in an image may provides for displaying at least one color test example that corresponds to at least one color vision capability condition, receiving an input selection corresponding to the at least one color vision capability condition, and altering a template for the plurality of colors based on the input selection. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Patent Office upon request and payment of the necessary fee.

Abstract: A porous glass rod is treated to include tungsten oxide and palladium in an arrangement that is sensitive to hydrogen to produce a color change that is a function of the hydrogen concentration. The rod is attached to the tip of a double fiber into one of which light is launched by a light source. A detector at the end of the second fiber is responsive to light reflected by the rod. The process for forming the rod includes the steps of doping the glass with a tungsten compound and a palladium compound with intervening and subsequent heating steps to bond the tungsten oxide and palladium to available oxygen atoms of the porous glass.

Abstract: A system for accessing data. The system includes a memory mechanism having the data. The system includes a mechanism for processing a query for the memory mechanism which is icon based. A system for accessing data. The system includes a memory mechanism having N heterogeneous memory sections having the data. The system includes a mechanism for processing queries for at least two of the N memory sections. A system for accessing data. The system includes a mechanism for processing queries along respective query paths for the memory mechanism. The processing mechanism has predefined query paths to process queries. A method for accessing data. A system for accessing data. The system includes a design time processing portion and a run time processing portion. A system for accessing data. The system includes a memory mechanism having N memory sections having the data. The system includes a mechanism for processing a query which simultaneously obtains data from the N memory sections. A system for accessing data.

Abstract: A controlled-release, drug-delivery, emulsion composition for topical application comprising (a) the reaction product of the non-aqueous, heterogeneous polymerization of a reaction mixture of about 5-70%, preferably 10-30%, by weight, of a vinyl monomer in an oil as solvent, and a free radical initiator, optionally in the presence of a crosslinking agent and/or a surfactant, wherein the oil solvent is present in an amount sufficient to keep the resultant polymer in a stirrable state throughout the polymerization, (b) water, (c) a surfactant and (d) a pharmaceutical medicament.

Abstract: A controlled release, drug-delivery tableted composition comprising, by weight, an uncrosslinked or crosslinked polymer of (a) about 5-40% of a vinyl amide, (b) about 10-70% of (meth)acrylic acid, (c) about 5-40% of a long chain alkyl (meth)acrylate or acrylamide, and (d) about 0-60% of a lower alkyl (meth)acrylate, and a pharmaceutical medicament.

Abstract: This invention relates to a fast drying iodine complex solution having film forming capability and skin substantivity which solution consists essentially of:(a) between 1 and 25 wt % polyvinyl pyrrolidone/iodine (PVP/I) complex;(b) between 5 and 15 wt % vinyl pyrrolidone/vinyl acetate copolymer (PVP/VA);(c) between 0.5 and 1.5 wt % non-plasticizing polyethylene glycol (PEG);(d) between 35 and 75 wt % C.sub.1 to C.sub.4 alkanol;(e) between 12 and 35 wt % deionized water and(f) between 0 and 2.5 wt % of 1-vinyl-3-(E)-ethylidene pyrrolidone, based on total composition.The invention also relates to the method of preparing the film forming solution which has a drying time of less than 5 minutes.

Abstract: A process for making a free-flowing, compressible powder by spraying a selected amount of an aqueous solution of polyvinylpyrrolidone onto a fluid bed containing a predetermined admixture of starch and polyvinylpyrrolidone therein, and drying. An active-containing tablet then is provided by adding an active material, optionally with a lubricant, to such powder, and compressing the admixture into a commercially acceptable tablet.